LACE‐Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry‐based Biomarkers in Resected Non–small‐cell Lung Cancer

Abstract

Background: Complete resection of non–small‐cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Materials and Methods: The LACE‐Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)‐9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. Results: The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and &bgr;‐tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches. Conclusions: Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE‐Bio‐2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC. Micro‐Abstract: There are no validated molecular tools to allow patient selection for adjuvant chemotherapy after complete resection of non–small‐cell lung cancer. Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. The majority of the promising biomarkers could not be validated, and none were predictive of benefit. Immunohistochemistry assays from single trials may be misleading.